Vertex Pharma's $4.9 billion takeover of Alpine Immune gives it access to a potential billion-dollar franchise, analyst says

Vertex Pharmaceuticals Inc.'s $4.9 billion acquisition of Alpine Immune Sciences Inc. makes strategic sense and will bolster the company's rare-disease franchise, analysts said Thursday.